Free Trial

Pacira BioSciences (PCRX) Competitors

Pacira BioSciences logo
$26.66 +0.01 (+0.04%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$26.64 -0.02 (-0.06%)
As of 09/19/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PCRX vs. PRGO, SUPN, NKTR, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRK

Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry.

Pacira BioSciences vs. Its Competitors

Pacira BioSciences (NASDAQ:PCRX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Pacira BioSciences has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$700.97M1.71-$99.56M-$2.78-9.59
Perrigo$4.37B0.67-$171.80M-$0.58-36.56

Pacira BioSciences currently has a consensus target price of $30.83, indicating a potential upside of 15.65%. Perrigo has a consensus target price of $33.00, indicating a potential upside of 55.62%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Perrigo
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

Pacira BioSciences has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

Perrigo has a net margin of -1.86% compared to Pacira BioSciences' net margin of -18.08%. Pacira BioSciences' return on equity of 13.29% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Pacira BioSciences-18.08% 13.29% 6.61%
Perrigo -1.86%9.09%3.96%

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.7% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Perrigo had 7 more articles in the media than Pacira BioSciences. MarketBeat recorded 9 mentions for Perrigo and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.17 beat Perrigo's score of 0.61 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacira BioSciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Perrigo
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Pacira BioSciences beats Perrigo on 10 of the 16 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCRX vs. The Competition

MetricPacira BioSciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.20B$3.15B$5.80B$10.40B
Dividend YieldN/A2.37%5.63%4.60%
P/E Ratio-9.5921.0580.5826.78
Price / Sales1.71450.04534.44123.53
Price / Cash6.1746.6037.9961.55
Price / Book1.589.6615.776.40
Net Income-$99.56M-$53.22M$3.30B$271.80M
7 Day Performance-1.70%3.11%5.36%3.49%
1 Month Performance6.68%7.56%8.10%9.90%
1 Year Performance83.48%11.15%81.36%28.62%

Pacira BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCRX
Pacira BioSciences
3.2869 of 5 stars
$26.66
+0.0%
$30.83
+15.7%
+81.5%$1.20B$700.97M-9.59720Positive News
High Trading Volume
PRGO
Perrigo
4.8409 of 5 stars
$21.76
-2.3%
$33.00
+51.7%
-23.6%$3.06B$4.37B-37.518,379Analyst Downgrade
SUPN
Supernus Pharmaceuticals
2.7523 of 5 stars
$43.99
-3.2%
$43.00
-2.3%
+43.3%$2.55B$661.82M38.25580Analyst Upgrade
NKTR
Nektar Therapeutics
4.1496 of 5 stars
$49.01
+0.7%
$88.33
+80.2%
+189.4%$925.82M$98.43M-5.57220Trending News
Analyst Forecast
OMER
Omeros
3.8224 of 5 stars
$4.09
-1.4%
$18.00
+340.1%
+3.7%$282.43MN/A-1.94210Analyst Upgrade
ASMB
Assembly Biosciences
3.4479 of 5 stars
$21.19
-3.0%
$41.33
+95.1%
+32.2%$167.64M$28.52M-3.80100Positive News
CPIX
Cumberland Pharmaceuticals
0.2996 of 5 stars
$3.38
-1.7%
N/A+146.1%$51.46M$37.87M-15.3680
LLY
Eli Lilly and Company
4.9971 of 5 stars
$748.26
-0.9%
$941.35
+25.8%
-17.7%$714.94B$45.04B48.9147,000Trending News
Analyst Forecast
JNJ
Johnson & Johnson
4.7111 of 5 stars
$177.49
-0.3%
$176.29
-0.7%
+6.8%$428.83B$88.82B18.98138,100Trending News
Analyst Forecast
ABBV
AbbVie
4.7705 of 5 stars
$217.92
-0.2%
$218.76
+0.4%
+14.8%$385.71B$56.33B103.7755,000Trending News
Analyst Forecast
Analyst Revision
MRK
Merck & Co., Inc.
4.9993 of 5 stars
$81.07
-2.1%
$107.44
+32.5%
-30.6%$206.84B$64.17B12.4975,000Trending News
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:PCRX) was last updated on 9/20/2025 by MarketBeat.com Staff
From Our Partners